ClinicaliQ Trial Snapshot
- A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 — Recruiting • Phase I / Phase II • NCT07179640.
- Early-stage trial testing a new drug (ALE1) for safety and effectiveness in healthy people and those with hypophosphatasia.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia (HPP). Conditions: Hypophosphatasia (HPP) Interventions: ALE1, Placebo Lead Sponsor: Alesta Therapeutics Planned Enrollment: 120 participants